(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Mummified cheetahs found in Saudi caves shed light on lost populations - 2Kona SUV: Exploring the Future with Hyundai's Visionary Hybrid
- 3Netflix Faces Wider Fallout After Italy Court Orders Refunds, Price Cuts
- 4I’m a doctor. Here are 10 science-backed tips to help you get healthier.
- 5Phenomenal Web-based MBA Stages for Proficient Headway
- Massachusetts court hears arguments in lawsuit alleging Meta designed apps to be addictive to kids
- First stop, the Moon. Next stop, Mars? Why Nasa's mission matters
- German gas price bill signed into law, but consumers not impressed
- Vote in favor of your Favored Travel Movement
- Rescuers again fail to free whale stranded on Germany's Baltic coast
- Reactions as Artemis II astronauts lift off on historic lunar mission
- A Pompeii site reveals the recipe for Roman concrete. It contradicts a famous architect’s writings
- Computerized Moderation: Tracking down Equilibrium in the Advanced Age
- Heading to Florida for NASA's Artemis 2 moon launch? Here's what to know before you go
